Biomerica, Inc. (BMRA), a biomedical technology firm, announced that it has received its first commercial order for Hp Detect, its diagnostic tool, from one of the largest clinical laboratory chains operating across Europe. The firm believes this order to have repeat order potential and may support future distribution discussions across the broader European market.
Following the news, BMRA is up 3.13% at $2.14.
Biomerica develops and manufactures diagnostic and therapeutic products for medical conditions and diseases.
Hp Detect is Biomerica's diagnostic stool antigen test, which indicates if a patient is infected with the Helicobacter pylori bacteria.
H. pylori is one of the most prevalent bacterial infections worldwide, estimated to infect 45% of the population across Europe's five largest countries.
The initial order for Hp Detect is for the United Kingdom market, where it received registration from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in February 2026.
"We also see this as a reference point as we pursue additional partnerships in the US and across the European market" said Zack Irani, Chief Executive Officer.
BMRA has traded between $1.87 and $5.92 in the last year. The stock closed Tuesday's trade at $2.08.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.